Elidel Generics Launched
December 27, 2018 – Teva Pharmaceuticals and Oceanside Pharmaceuticals have launched generic versions of Novartis’s Elidel® (pimecrolimus) cream 1%. Teva’s launch occurred on December 27, 2018, one week after Oceanside’s December 20 launch.
Pimecrolimus cream 1% is indicated as a second-line therapy for short-term, noncontinuous chronic treatment of mild to moderate atopic dermatitis in patients who are at least two years old. Under this indication, pimecrolimus cream should only be used in non-immunocompromised individuals who are poor candidates for, or have not had an adequate response to, other topical prescription treatments.
Under the recommended dosing, a thin layer of pimecrolimus cream should be applied to the affected skin twice daily. The product should not be used for longer than six weeks. Patients whose signs and symptoms persist beyond six weeks should see their healthcare provider. A black box warning cautions that rare cases of malignancy, including skin cancer and lymphoma, have been reported in patients treated with topical calcineurin inhibitors, including pimecrolimus cream. However, a causal relationship has not been established.
Teva’s generic is available at a wholesale acquisition cost (WAC) of $812.51 for a 100g tube, compared to $845.43 for Oceanside’s generic and $996.83 for brand name Elidel.